Results for the substance abrocitinib

Abrocitinib is a medication used for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and adolescents who do not respond adequately to topical therapies or for whom such treatments are not suitable. It belongs to the class of Janus kinase (JAK) inhibitors, which work by blocking the activity of certain enzymes involved in inflammatory processes.

By inhibiting JAK1, abrocitinib reduces inflammation and symptoms associated with atopic dermatitis, such as intense itching, redness, and skin lesions. The medication is taken orally, usually once daily, as directed by a doctor.

Common side effects include nausea, headache, upper respiratory tract infections, and increased levels of certain liver enzymes or blood lipids. Rarely, more severe reactions such as serious infections, blood clots (thrombosis), or hematological abnormalities may occur.

Patients taking abrocitinib should be regularly monitored, including blood tests to assess liver function, lipid levels, and other parameters. It is important for patients to inform their doctor about any other medications they are taking, as abrocitinib may interact with certain treatments.

Patients should also avoid exposure to infections, as the medication can weaken the immune system. The use of abrocitinib during pregnancy or breastfeeding is not recommended, and women of childbearing potential should use effective contraception during treatment.